Reply to Lund et al
Am J Physiol Endocrinol Metab
.
2023 Oct 1;325(4):E423-E424.
doi: 10.1152/ajpendo.00283.2023.
Authors
Dalia Barayan
1
2
3
,
Fadi Khalaf
2
,
Carly M Knuth
1
2
3
,
Abdikarim Abdullahi
1
2
,
Sarah Rehou
4
2
3
,
Robert A Screaton
1
2
5
,
Marc G Jeschke
1
6
7
4
2
8
3
Affiliations
1
Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
2
Sunnybrook Research Institute, Toronto, Ontario, Canada.
3
Hamilton Health Sciences, Hamilton, Ontario, Canada.
4
Ross Tilley Burn Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
5
Department of Biochemistry, University of Toronto, Toronto, Canada.
6
Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
7
Division of Plastic and Reconstructive Surgery, Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
8
Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
PMID:
37812085
PMCID:
PMC10642985
(available on
2024-10-01
)
DOI:
10.1152/ajpendo.00283.2023
No abstract available
Keywords:
MCT1 inhibitor; Na-l-lactate; burn; sepsis.
Publication types
Letter
Research Support, N.I.H., Extramural
Comment
Grants and funding
R01 GM087285/GM/NIGMS NIH HHS/United States